Hormone replacement therapy with estradiol and risk of venous thromboembolism. A population-based case-control study

Thrombosis and Haemostasis

Volumn 82, Issue 4, 1999, Pages 1218-1221

  Høibraaten, Else ^a   Abdelnoor, Michael ^a   Sandset, Per Morten ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Case control study; Estradiol; Hormone replacement therapy; Venous thromboembolism

Indexed keywords

ESTRADIOL;

ADULT; AGED; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG FORMULATION; ESTROGEN THERAPY; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING HABIT; STATISTICAL ANALYSIS; THROMBOEMBOLISM;

EID: 0032851667     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614363     Document Type: Article

References (15)

1. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in woman. JAMA 1991; 265: 1861-67.
2. Hulley S, Grady D, Bush T, Furherg C, Herrington D, Riggs B Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
3. Report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. Surgically confirmed gallbladder, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 1974; 290: 15-9.
4. Pettiti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women: Smoking, oral contraceptives, non-contraceptive estrogens, and other factors. JAMA 79; 242; 1150-4.
5. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol 1979; 133: 525-36.
6. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy. II. A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74-9.
7. Devor M, Barrett-Connor E, Renvall M, Feigal D, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-84.
8. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
9. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7.
10. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens. Lancet 1996; 348: 981-3.
11. Gutthann SP, Rodriguez LAG, Castellsague J. Oliart AD. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314: 796-800.
12. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 1998; 147: 387-90.
13. Schlessman JJ, ed. Case-control Studies: Design, Conduct, and Analyses. Oxford University Press, Oxford, 1992.
14. Kleinbaum D, Kupper L, Morgenstern H, eds. Epidemiologic Research. Principles and Quantitative Methods. Van Nostrand Reinhold Compagny, New York, 1982.
15. Øydvin K, ed. Drug Consumption in Norway 1993-1997. Norwegian Medicinal Depot, Oslo, 1998.